Abstract
To alert patients and health care providers about the use of energy-based devices to perform a vaginal “rejuvenation,” cosmetic vaginal procedures, or nonsurgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function, the US Food and Drug Administration (FDA) has issued a warning about the effectiveness and safety of such devices. We agree with the FDA that certain devices (laser, radiofrequency, etc.) have been marketed inappropriately for uses that are outside of their cleared or approved intended uses. We want to position ourselves in the strict training of professionals so that the indications and techniques are used in the best possible way, knowing that, similar to any medical or surgical technique, the side effects can appear in the short and long term, and should be recognized and remedied.
This is a preview of subscription content, log in via an institution to check access.
References
FDA Warns Against Use of Energy-Based Devices to Perform Vaginal “Rejuvenation” or Vaginal Cosmetic Procedures: FDA safety communication. Date Issued: July 30, 2018
The American College of Obstetricians and Gynecologists. Fractional laser treatment of vulvovaginal atrophy and US Food and Drug Administration clearance: position statement. May 2016
Portman DJ, Gass ML (2014) Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med 11(12):2865–2872
Bachmann G, Santen RJ (2018) Treatment of genitourinary syndrome of menopause (vulvovaginal atrophy). UpToDate
Salvatore S, Athanasiou S, Candiani M (2015) The use of pulsed CO2 lasers for the treatment of vulvovaginal atrophy. Curr Opin Obstet Gynecol 27(6):504–508
González-Isaza P, Sánchez-Borrego R, Escribano JJ, Zerbinati N, Tserotas K, Leibaschoff G (2018 June) Letters To the editor. Menopause 25(6):710
Krychman M, Rowan CG, Allan BB, Durbin S, Yacoubian A, Wilkerson D (2018) Effect of single-session, cryogen-cooled monopolar radiofrequency therapy on sexual function in women with vaginal laxity: the VIVEVE I trial. J Women’s Health 27(3):297–304
Blaganje M, Šćepanović D, Žgur L, Verdenik I, Pajk F, Lukanović A (2018) Non-ablative Er:YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol 224:153–158
Pitsouni E, Grigoriadis T, Falagas ME et al (2017) Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas 103:78
Arunkalaivanan A, Kaur H, Onuma O (2017) Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence. Int Urogynecol J 28:681–685
Author information
Authors and Affiliations
Contributions
All authors contributed equally to writing this editorial.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Escribano, J.J., González-Isaza, P., Tserotas, K. et al. In response to the FDA warning about the use of photomedicine in gynecology. Lasers Med Sci 34, 1509–1511 (2019). https://doi.org/10.1007/s10103-019-02744-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10103-019-02744-1